Reporting Adverse Drug Reactions: A guide for healthcare professionals


May 2006

References
  1. BMA (1996) Reporting adverse drug reactions – a BMA policy document. London: BMA.
  2. Rawlins M (1994) Pharmacovigilance: paradise lost, regained or postponed? Journal of the Royal College of Physicians of London 29:1.
  3. BMA (2005) Over-the-counter medication. London: BMA. At www.bma.org.uk/ap.nsf/Content/OTCmedication?OpenDocument&Highlight=2,over,counter (accessed March 2006).
  4. MHRA website, Safety information: What to report. At www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&nodeId=750 (accessed March 2006)
  5. British National Formulary (2005) BNF49. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain.
  6. MHRA website, Safety information: What to report, Causality. At www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&nodeId=754 (accessed March 2006)
  7. PRODIGY Guidance – adverse drug reactions. At www.prodigy.nhs.uk/ProdigyKnowledge/Guidance/WholeGuidanceView.aspx?GuidanceId=37273 (accessed March 2006).
  8. Pirmohamed M, Breckendridge A & Kitteringham N et al (1998) Fortnightly review, Adverse drug reactions. BMJ 316: 1295-8.
  9. Pirmohamed M, James S & Meakin S et al (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 329: 15-9.
  10. Lazarou J, Pomeranz H & Corey P (1998) Incidence of Adverse Drug Reactions in Hospitalized Patients, A mete-analysis of prospective studies. JAMA 279: 15 1200-5.
  11. Pirmohammed M, (2006), personal communication.
  12. Gandhi T, Weingart S & Borus J et al (2003) Adverse drug events on ambulatory care. New England Journal of Medicine 348: 16
  13. World Health Organisation (2004) WHO policy perspectives on medicines – pharmacovigilance: ensuring the safe use of medicines. Geneva: WHO.
  14. Stiker B & Psaty B (2004) Detection, verification, and quantification of adverse drug reactions. BMJ 329: 44-7.
  15. MHRA website, How we regulate: Medicines in Children. At www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&nodeId=132 (accessed March 2006).
  16. The Academy of Medical Sciences (2005) Safer Medicines. UK: The Academy of Medical Sciences.
  17. GMC (2001) Good medical practice (3e). London: General Medical Council.
  18. Davis S & Coulson R (1999) Community pharmacist reporting of suspected ADRs: the first year of the yellow card demonstration scheme. Pharmaceutical Journal 263: 7071.
  19. Van Grootheest K, Olsson S & Couper M et al (2004) Pharmacists’ role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiology and Drug Safety 13: 457-464.
  20. Morrison-Griffiths S, Walley T & Park B et al (2003) Reporting of adverse drug reactions by nurses. The Lancet 361:1347.
  21. MHRA website, Safety information: Healthcare professional reporting, Black Triangle Scheme. At www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&nodeId=748 (accessed March 2006)
  22. MRHA website, Safety information: Safety warnings and messages for medicines. At www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON2015714&ssTargetNodeId=221 (accessed March 2006).
  23. MHRA/CSM (2003) Possible interaction between warfarin and cranberry juice. Current Problems in Pharmacovigilance 29: 8.
  24. MHRA/CSM (2004) Interaction between warfarin and cranberry juice: new advice. Current Problems in Pharmacovigilance 30: 10.
  25. BNF for Children website at www.bnfc.org (accessed March 2006).
  26. Lee A (ed) (2005) Adverse drug reactions. UK: Pharmaceutical press.
  27. De Smet PAGM (2002) Herbal remedies. N Eng J Med 347: 2046-56.
  28. Medicines Control Agency (2002) Consultation letter MLX 286: Proposals to prohibit the herbal ingredient Kava-kava (Piper methysticum) in unlicensed medicines. At www.mhra.gov.uk/home/groups/comms-ic/documents/publication/con007613.pdf (accessed March 2006).
  29. Report of an Independent Review of Access to the Yellow Card Scheme (2004). London: TSO. At www.mhra.gov.uk/home/groups/comms-ic/documents/websiteresources/con2015008.pdf (accessed March 2006).
  30. http://medguides.medicines.org.uk/mip.aspx (accessed March 2006).
  31. Data Protection Act 1998: www.hmso.gov.uk/acts/acts1998/19980029.htm
  32. MHRA website, Safety information: Patient reporting. At www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&nodeId=755 (accessed March 2006).
  33. MHRA website, Safety information: What happens to a Yellow Card. At www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&nodeId=623 (accessed March 2006)
  34. Jefferys D, Leakey D & Lewis J et al (1998) New active substances authorised in the United Kingdom between 1972 and 1994. British Journal of Clinical Pharmacology 45: 151-6.
  35. Department of Health, Public Health Link website at www.info.doh.gov.uk/doh/embroadcast.nsf (accessed March 2006).
  36. MHRA website, Safety information: How we monitor the safety of products, Devices. At www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&nodeId=280 (accessed 2006).
  37. General Practice Research Database website at www.gprd.com/home (accessed March 2006)
  38. Drug Safety Research Unit (DRSU) website at www.drsu.org (accessed March 2006).
  39. The Tayside Medicines Monitoring Unit (MEMO) website at www.dundee.ac.uk/memo (accessed March 2006)
  40. The Health Improvement Network (THIN) website at www.thin-uk.com (accessed March 2006).
  41. QResearch website at www.nottingham.ac.uk/~mczqres (accessed March 2006).
  42. General Practice Research Database website, Services and products: price plans. At www.gprd.com/serviceofferings/priceplan.asp (accessed March 2006).
  43. Medical Research Council website at www.mrc.ac.uk/index/current-research/current-resources/research_gprd (accessed March 2006).
  44. Eudravigilance website at http://eudravigilance.emea.eu.int/human/index.asp (accessed March 2006).
  45. WHO Programme for International Drug Monitoring website at www.who-umc.org/DynPage.aspx?id=13140&mn=1514 (accessed March 2006).
  46. Wong I (1999) Pharmacovigilance resources in the United Kingdom. Pharmaceutical Journal 263: 7059.
  47. Heeley E, Riley J, & Layton D et al (2001) Prescription-event monitoring and reporting adverse drug reactions. The Lancet 358: 1872-3.
  48. Inman WHW (1976) Detection and investigation of drug safety problems (eds) Gent M & Shagamatsu I. In Epidemiological issues in reported drug induced illnesses. Canada: McMaster University Library Press.
  49. Belton K, Lewis S &Payne S et al (1995) Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. British Journal of Clinical Pharmacology 39: 223-6.
  50. Herdeiro M, Polonia J &Gestal-Otero J et al (2004) Factors that influence spontaneous reporting of adverse drug reactions: a model centralized in the medical profession. Journal of evaluation in clinical practice 10: 4.
  51. Figueiras A, Tato F & Fontainas J et al (2001) Physicians’ attitudes towards voluntary reporting of adverse drug events. Journal of evaluation in clinical practice 7: 4.
  52. Elland I, Belton, K & van Grootheest A et al (1999) Attitudinal survey of voluntary reporting of adverse drug reactions. British Journal of Clinical Pharmacology 48: 623-7.
  53. Bracchi R, Houghton J & Woods F et al (2005) A distance-learning programme in pharmacovigilance linked to educational credits is associated with improved reporting of suspected adverse drug reactions via the UK yellow card scheme. British Journal of Clinical Pharmacology 60: 2, 221-3.
  54. Cox A, Marriott J & Wilson K (2004) Adverse drug reaction teaching in UK undergraduate medical and pharmacy programmes. Journal of Clinical Pharmacy and Therapeutics 29: 31-5.
  55. Maxwell S & Walley T (2003) Teaching safe and effective prescribing in UK medical schools: a core curriculum for tomorrow’s doctors. British Journal of Clinical Pharmacology 55: 496-503.
  56. Corry M, Bonner M & McEntee S et al (1999) Hospitals do not inform GPs about medication that should be monitored. Family Practice 17: 3.
  57. Cockayne N, Duguid M & Shenfield G (2004) Health professionals rarely record history of complementary and alternative medicines. British Journal of Clinical Pharmacology 59:2, 254-8.
  58. British Heart Foundation website at www.bhf.org.uk/professionals/index.asp?secID=15&secondlevel=471&thirdlevel=1514&artID=7240 (accessed January 2006).
  59. Email correspondence with Jeremy Thorp, Director of Business Requirements, Technology Office, NHS Connecting for Health (October 2005).

    © British Medical Association 2008

Log in to your BMA here